Controlled Clinical Trials 1995: Vol 16 Index

9 Pages·1995·2.4 MB·English

e1%;
ELSEVIER
Author Index for Volume 16
Amoroso WP, 104S Fairweather WR, 456 Kelder SH, 96
Anderson JJ, 342 Fayers P, 173 Knatterud GL, 139
Applegate WB, 41 Feig] P, 150 Koch HJ, 182
Arango IG, 422 Feldman HA, 96 Kramer BS, 150
Armitage P, 259 Felson DT, 342 Kuntz TE, 104S
Fleming TR, 408 Kupfer D, 17
Bagniewska A, 66S Ford LG, 150
Bailey LR, 30S Foulkes M, 408 Lakatos E, 96
Baldwin W, 300 Foulkes MA, 277, 310 Leahy KA, 51
Barnes TY, 164 Frank E, 17 Lewis SM, 89
Barton F, 432 Fraser WD, 299 Lind BK, 4S
Bayer DP, 187 Freedman LS, 277, 310 Liu P-Y, 119
Benson V, 3 Friedman L, 277, 310 LoPresti F, 30S
Blumenstein B, 150, 453
Blumenstein BA, 4S Gail MH, 230 Mantel N, 197, 214
Boissel J-P, 286, 319 Gassman JJ, 1045S Martin JP, 104S
Borok GM, 3 Geller NL, 277, 310 Mayer KH, 408
Brawley OW, 150, 293 George VA, 422 McBride R, 1S, 137S
Bring J, 131 Gerace TA, 422 McCormick M, 41
Buist AS, 184, 296 Germanson TP, 164 McFadden ET, 30S
Gibson D, 173, 455 McKenna C, 89
CATCH Study Group, 96 Girard P, 319 McKinlay SM, 96
Charache S, 432 Goldman S, 331 McMahon RP, 432
Chauvin F, 319 Gordon DJ, 41, 277, 310 Meinert C, 139
Chernoff MC, 342 Gore SM, 289 Meinert CL, 304, 363
Childress JF, 408 Green SB, 189 Menzin J, 3
Choi SC, 164 Greenhouse J, 17 Mitchell HE, 4S
Clarke E, 30S Greenhouse SW, 191, 214 Moher D, 62
Clarke WR, 301 Greenlick MR, 296 Moore R, 432
Cohen MC, 89 Griffiths RI, 377 Moritz T, 331
Moses LE, 216
Coltman CA, Jr, 150 Gueyffier F, 286
Mossman J, 173
Comstock GW, 133
Copeland J, 331 Harrington M, 270 Mowery R, 277, 310
Muller JE, 89
Crowley J, 150 Harvey AJ, 455
Multicenter Study of
Curtis RC, 41 Haugh M, 286, 319
Hydroxyurea, 432
Hawkins BS, 66S, 458
Dahlberg S, 119 Henderson WG, 331 Murray DM, 96
Davis CE, 41 Hertert S, 184
DeMets DL, 408 Heyse JF, 3 Nader PR, 96
Dover G, 432 Horbar JD, 51 Newhouse MM, 66S
Doyle SR, 451 Hosking JD, 66S Ng T-H, 356
Nichol G, 62
Dudl RJ, 3
Durieu I, 319 Jadad AR, 62 Nony P, 319
James KE, 4S
Eckert S, 432 Jones MF, 301 OFallon J, 408
Ellenberg SS, 408 Omoigui NA, 143
Epstein A, 3 Kadane JB, 313 Osborne ML, 184
Epstein RS, 3 Kamlet MS, 17 Oster G, 3
Controlled Clinical Trials 16:460-461 (1995)
© Elsevier Science Inc. 1995 0197-2456/95/$9.50
655 Avenue of the Americas, New York, NY 10010 SSDI 0197-2456(95)00191-3
Author Index for Volume 16 461
Overall JE, 451 Schneiderman MA, 193, 214 Vermont-Oxford Trials
Owen WW, 104S Sethi G, 331 Network, 51
Shih JH, 395 Vollmer WM, 184
Parmar MKB, 455 Simon R, 277, 310
Paul N, 17 Singer SW, 1S, 137S, 363 Waclawiw M, 432
Penman M, 62 Stevens MT, 447 Wade M, 17
Piantadosi S, 202, 214, 307 Straus S, 408 Walsh S, 62
Pollard RB, 408 Walters L, 408
Powe NR, 377 . Wang M, 342
Terrin ML, 432 Webber LS, 96
Prentice RL, 249 The SvO, Collaborative Whitley RJ, 408
Quinn V, 3 Group, 74 Whitley-Williams P, 408
gle Wilkins PC, 30S
Rahal JJ, 408 Topol EJ, 143 Wittes JT, 1
Rochon J, 449 Torner JC, 301 Wolf M, 150
Tugwell P, 62 Woolson RF, 301
Sande M, 408
Sato T, 359 Uryniak TJ, 447 © Zucker DM, 96
|
mm W1k ;
ELSEVIER
Subject Index for Volume 16
ABSTRACTS BYAR, DAVID P., M.D.
Abstracts from the Sixteenth Annual Byar, David P., M.D., 187
Meeting of the Society for Clinical
Trials, 3S CANCER CLINICAL TRIALS
UKCCCR Register of U.K. Cancer Trials,
ADHERENCE 172
An Empirical Evaluation of the Placebo
CANCER EPIDEMIOLOGY
Run-in, 41
David Byar’s Approach to the Analysis of
Survival Data with Covariates, 259
AIDS
The Data and Safety Monitoring Board and
CHECKLISTS
Acquired Immune Deficiency
Assessing the Quality of Randomized
Syndrome (AIDS) Clinical Trials,
Controlled Trials: An Annotated
408
Bibliography of Scales and
In Memoriam: David Byar as an AIDS
Checklists, 62
Activist, 170
CHEMOPREVENTION
ANGIOPLASTY
Design of the Prostate Cancer Prevention
Observational versus Randomized Medical Trial (TCPT), 150
Device Testing Before and After
Approval-— The Atherectomy- CLINICAL ECONOMICS
versus-Angioplasty Controversy, The Clinical-Economic Trial: Promise,
143 Problems, and Challenges, 377
ASSESSMENT CLINICAL TRIALS
Assessing the Quality of Randomized A Simple Measure in Defining Optimal
Controlled Trials: An Annotated Strata in Clinical Trials, 164
Bibliography of Scales and
Checklists, 62 CLINICAL TRIAL
An Assessment of Data Quality in the
Vermont-Oxford Trials Network
ATHERECTOMY
Database, 51
Observational versus Randomized Medical
Device Testing Before and After
CLINICAL TRIALS
approval — The Atherectomy-
An Empirical Evaluation of the Placebo
versus-Angioplasty Controversy,
Run-in, 41
143
The Clinical-Economic Trial: Promise,
Problems, and Challenges, 377
BIASED ASCERTAINMENT
Commentary regarding “Inclusion of
Design of the Prostate Cancer Prevention
Women and Minorities in Clinical
Trial (TCPT), 150
Trials and the NIH Revitalization Act
of 1993—The Perspective of the
BOOK REVIEWS NIH Clinical Trialists,” 307
Clinical Data Management, ed. Rondel RK, Comments on NIH Clinical Trials Valid
Varley SA, and Webb, CF, 458 Analysis Requirements, 304
Drug Safety Assessment in Clinical Trials, The Data and Safety Monitoring Board and
by Sogliero-Gilbert G, 456 Acquired Immune Deficiency
Controlled Clinical Trials 16:462-468 (1995)
© Elsevier Science Inc. 1995 0197-2456/95/$9.50
655 Avenue of the Americas, New York, NY 10010 SSDI 0197-2456(95)00192-1
Subject Index for Volume 16
Syndrome (AIDS) Clinical Trials, COORDINATING CENTERS
408 Functions and Organization of
David Byar’s Approach to the Analysis of Coordinating Centers for
Survival Data with Covariates, 259 Multicenter Studies, 4S
Discussion of “Inclusion of Women and
Minorities in Clinical Trials and the COST-BENEFIT STUDIES
NIH Revitalization Act of 1993 — The The Clinical-Economic Trial: Promise,
Perspective of NIH Clinical Problems, and Challenges, 377
Trialists,” 301
Format-Independent Data Collection COST EFFECTIVENESS
Forms, 363 A Randomized Trial to Assess Effectiveness
Inpact of the NIH Inclusion Guidelines, 300 and Cost in Clinical Practice:
Inclusion of Women and Minorities in Rationale and Design of the
Clinical Trials, 290 Cholesterol Reduction Intervention
Study (CRIS), 3
Inclusion of Women and Minorities in
Clinical Trials and the NIH
Revitalization Act of 1933—The COST-EFFECTIVENESS STUDIES
The Clinical-Economic Trial: Promise,
Perspective of NIH Clinical
Problems, and Challenges, 377
Trialists, 277
Problems and Suggested Solutions in
COST-UTILITY ANALYSIS
Creating an Archive of Clinical
Cost Utility Analysis of Maintenance
Trials Data to Permit Later
Treatment for Recurrent
Meta-Analysis: An Example of
Depression, 17
Methotrexate Trials in Rheumatoid
Arthritis, 342
CRITICALLY ILL PATIENT
Response Rates to Six Recruitment Mailing
The SvO, Study, General Design and
Formats and Two Messages about a
Results of the Feasibility Phase of a
Nutrition Program for Women
Multicenter, Randomized Trial of
50-79 Years Old, 422
Three Different Hemodynamic
Response to Discussants’ Letters, 310
Approaches and Two Monitoring
Response to “Inclusion of Women and
Techniques in the Treatment of
Minorities in Clinical Trials and the
Critically Il] Patients, 74
NIH Revitalization Act of 1993 —the
Perspective of NIH Clinical
DATA AND SAFETY
Trialists, 286, 289, 293, 296, 299
MONITORING BOARDS
Use of Cumulative Meta-Analysis in the
The Data and Safety Monitoring Board and
Design, Monitoring, and Final
Acquired Immune Deficiency
Analysis of a Clinical Trial: A Case
Syndrome (AIDS) Clinical Trials,
Study, 331
408
CLINIMETRICS
DATA COLLECTION
Assessing the Quality of Randomized
Format-Independent Data Collection
Controlled Trials: An Annotated
Forms, 363
Bibliography of Scales and
Checklists, 62
DATA ENTRY
Response to Dr. Blumenstein’s Letter
CLUSTER RANDOMIZATION (letter), 455
Statistical Design of the Child and
Adolescent Trial for Cardiovascular DATA MANAGEMENT
Health (CATCH): Implications of Approaches to Data Management, 30S
Cluster Randomization, 96 Data Collection and Transcription, 66S
Data Management for Multicenter Studies:
COMMUNITY STUDIES Methods and Guidelines, 1S
Statistical Design of the Child and Data Quality Assurance, Monitoring, and
Adolescent Trial for Cardiovascular Reporting, 104S
Health (CATCH): Implications of Interim Reports, Participant Closeout, and
Cluster Randomization, 96 Study Archives, 137S
Subject Index for Volume 16
DATA QUALITY Epidemiology, 230
An Assessment of Data Quality in the
Vermont-Oxford Trials Network EQUIVALENCE STUDIES
Database, 51 Conventional Null Hypothesis Testing in
Active Control Equivalence
DATABASE Studies, 356
An Assessment of Data Quality in the
Vermont-Oxford Trials Network ERROR RATES
Database, 51 An Assessment of Data Quality in the
Vermont-Oxford Trials Network
DAVID BYAR Database, 51
David Byar’s Approach to the Analysis of
Survival Data with Covariates, 259 FETAL HEMOGLOBIN
Design of the Multicenter Study of
DEVICE APPROVAL : Hydroxyurea in Sickle Cell Anemia,
Observational versus Randomized Medical 432
Device Testing Before and After
Approval — The Atherectomy- FIRST ADMINISTRATION
versus-Angioplasty Controversy, Dose-Ranging Trials: Guidelines for Data
Collection and Standardized
143
Descriptions, 319
DISCRIMINANT REGIONS
A Simple Measure in Defining Optimal FISHER’s LSD APPROACH
Design and Analysis of Multiarm Clinical
Strata in Clinical Trials, 164
Trials with Survival Endpoints, 119
DISEASE PREVENTION TRIALS
FOLLOW-UP STUDIES
On the Role, Design, and Analysis of
Format-Independent Data Collection
Disease Prevention Trials, 249
Forms, 363
DOSE RANGING
FOOD AND DRUG ADMINISTRATION
Dose-Ranging Trials: Guidelines for Data
Observational versus Randomized Medical
Collection and Standardized
Device Testing Before and After
Descriptions, 319
Approval— The Atherectomy-
versus-Angioplasty Controversy,
DRUG THERAPY
A Randomized Trial to Assess Effectiveness 143
and Cost in Clinical Practice:
FORM PRODUCTION
Rationale and Design of the
Format-Independent Data Collection
Cholesterol Reduction Intervention
Forms, 363
Study (CRIS), 3
GROUP RANDOMIZATION
ECONOMIC INVESTIGATION
Statistical Design of the Child and
The Clinical-Economic Trial: Promise,
Adolescent Trial for Cardiovascular
Problems, and Challenges, 377
Health (CATCH): Implications of
Cluster Randomization, 96
EDUCATION
An Empirical Evaluation of the Placebo
HEAD INJURY
Run-in, 41
A Simple Measure in Defining Optimal
Strata in Clinical Trials, 164
ELICITATION
Prime Time for Bayes, 313
HEMODYNAMICS
The SvO, Study: General Design and
EPIDEMIOLOGIC METHODS Results of the Feasibility Phase of a
The Clinical-Economic Trial: Promise, Multicenter, Randomized Trial of
Problems, and Challenges, 377 Three Different Hemodynamic
Approaches and Two Monitoring
EPIDEMIOLOGY Techniques in the Treatment of
David Byar’s Contribution to Critically Ill Patients, 74
Subject Index for Volume 16 465
HOTELLINGS T? Response to S.J. Day’s Letter, 447
Comment on the Substitution of z for t and Sample Size Calculations for Repeated
on Hotelling’s T* for Repeated Measures Experiments, 449
Measures (letter), 451
LOGRANK TEST
HYDROXYUREA Design and Analysis of Multiarm Clinical
Design of the Multicenter Study of Trials with Survival Endpoints, 119
Hydroxyurea in Sickle Cell Anemia,
432 LOSS FUNCTION
Prime Time for Bayes, 313
HYPERCHOLESTEROLEMIA
A Randomized Trial to Assess Effectiveness MAILINGS
and Cost in Clinical Practice: Response Rates to Six Recruitment Mailing
Rationale and Design of the Formats and Two Messages about a
Cholesterol Reduction Intervention Nutrition Program for Women
Study (CRIS), 3 50-79 Years Old, 422
INTENSIVE CARE MANTEL — HAENSZEL STATISTIC
The SvO, Study: General Design and A Simple Measure in Defining Optimal
Results of the Feasibility Phase of a Strata in Clinical Trials, 164
Multicenter, Randomized Trial of
Three Different Hemodynamic MARK-UP LANGUAGE
Approaches and Two Monitoring Format-Independent Data Collection
Techniques in the Treatment of
Forms, 363
Critically Ill Patients, 74
MARKOV MODEL
INTENTION-TO-TREAT PRINCIPLE Sample Size Calculation for Complex
Statistical Design of the Child and Clinical Trials with Survival
Adolescent Trial for Cardiovascular Endpoints, 395
Health (CATCH): Implications of
Cluster Randomization, 96 MEASUREMENT
Comment on the Substitution of z for t and
INTERACTIONS on Hotelling’s T? for Repeated
David Byar’s Approach to the Analysis of Measures (letter), 451
Survival Data with Covariates, 259
META-ANALYSIS
INTERIM REPORTING Problems and Suggested Solutions in
Interim Reports, Participant Closeout, and Creating an Archive of Clinical
Study Archives, 137S Trials Data to Permit Later
Meta-Analysis: An Example of
LAG TIME Methotrexate Trials in Rheumatoid
Sample Size Calculation for Complex Arthritis, 342
Clinical Trials with Survival Use of Cumulative Meta-Analysis in the
Endpoints, 395 Design, Monitoring, and Final
Analysis of a Clinical Trial: A Case
LEAST FAVORABLE ALTERNATIVE Study, 331
Design and Analysis of Multiarm Clinical
Trials with Survival Endpoints, 119 MINORITIES
Commentary Regarding “Inclusion of
LETTERS TO THE EDITOR Women and Minorities in Clinical
Comment on the Substitution of z for t and Trials and the NIH Revitalization Act
on Hotelling’s T? for Repeated of 1993—The Perspective of NIH
Measures, 451 Clinical Trialists,” 307
A Further Look at the Comments on NIH Clinical Trials Valid
Cochran-Mantel-Haenszel Risk Analysis Requirements, 304
Difference, 359 Discussion of “Inclusion of Women and
Medical Research Data, 453 Minorities in Clinical Trials and the
Response to Dr. Blumenstein’s Letter, 455 NIH Revitalization Act of 1993 — The
Subject Index for Volume 16
Perspective of NIH Clinical Women and Minorities in Clinical
Trialists,” 301 Trials and the NIH Revitalization Act
Inclusion of Women and Minorities in of 1993 — The Perspective of NIH
Clinical Trials, 290 Clinical Trialists,” 307
Inclusion of Women and Minorities in Comments on NIH Clinical Trials Valid
Clinical Trials and the NIH Analysis Requirements, 304
Revitalization Act of 1933—The Discussion of “Inclusion of Women and
Perspective of NIH Clinical Minorities in Clinical Trials and the
Trialists,” 277 NIH Revitalization Act of 1993 —The
Response to Discussants’ Letters, 310 Perspective of NIH Clinical
Response to “Inclusion of Women and Trialists,” 301
Minorities in Clinical Trials and the Impact of the NIH Inclusion Guidelines,
NIH Revitalization Act of 1993 — The 300
Perspective of NIH Clinical Inclusion of Women and Minorities in
Trialists,” 286, 289, 293, 296, 299 Clinical Trials, 290
Inclusion of Women and Minorities in
MIXTURE SURVIVAL MODEL Clinical Trials and the NIH
Cost Utility Analysis of Maintenance Revitalization Act of 1933—The
Treatment for Recurrent Perspective of NIH Clinical
Depression, 17 Trialists, 277
Response to Discussants’ Letters, 310
MONITORING TECHNIQUES Response to “Inclusion of Women and
Design of the Prostate Cancer Prevention Minorities in Clinical Trials and the
Trial (TCPT), 150 NIH Revitalization Act of 1993 —the
Perspective of NIH Clinical
MONTE CARLO SIMULATION Trialists,” 286, 289, 293, 296, 299
Cost Utility Analysis of Maintenance
Treatment for Recurrent NONPROPORTIONAL HAZARDS
Depression, 17 Sample Size Calculation for Complex
Clinical Trials with Survival
MULTICENTER STUDIES Endpoints, 395
Data Management for Multicenter Studies:
Methods and Guidelines, 1S NULL HYPOTHESIS
Functins and Organization of Coordinating Conventional Null Hypothesis Testing in
Centers for Multicenter Studies, 4S Active Control Equivalence
Studies, 356
MULTILEVEL MODELING
Statistical Design of the Child and OBJECTIVITY
Adolescent Trial for Cardiovascular Prime Time for Bayes, 313
Health (CATCH): Implications of
Cluster Randomization, 96 OBSERVATIONAL DATA
Observational versus Randomized Medical
MULTIPLE COMPARISON Device Testing Before and After
Design and Analysis of Multiarm Clinical Approval-The Atherectomy-versus-
Trials with Survival Endpoints, 119 Angioplasty Controversy, 143
NEONATE OPTICAL CATHETER
An Assessment of Data Quality in the The SvO, Study: General Design and
Vermont-Oxford Trials Network Results of the Feasibility Phase of a
Database, 51 Multicenter, Randomized Trial of
Three Different Hemodynamic
NETWORK Approaches and Two Monitoring
An Assessment of Data Quality in the Techniques in the Treatment of
Vermont-Oxford Trials Network Critically Ill Patients, 74
Database, 51
OXYGEN DELIVERY
NIH REVITALIZATION ACT The SvO, Study: General Design and
Commentary Regarding “Inclusion of Results of the Feasibility Phase of a
Subject Index for Volume 16
Multicenter, Randomized Trial of QUALITY
Three Different Hemodynamic Assessing the Quality of Randomized
Approaches and Two Monitoring Controlled Trials: An Annotated
Techniques in the Treatment of Bibliography of Scales and
Critically Il] Patients, 74 Checklists, 62
PARTICIPANT CLOSEOUT QUALITY ASSURANCE
Interim Reports, Participant Closeout, and Data Quality Assurance, Monitoring, and
Study Archives, 137S Reporting, 104S
PHASE I STUDY
RANDOMIZED CLINICAL TRIAL
Dose-Ranging Trials: Guidelines for Data A Randomized Trial to Assess Effectiveness
Collection and Standardized and Cost in Clinical Practice:
Descriptions, 319 Rationale and Design of the
Cholesterol Reduction Intervention
PLACEBO Study (CRIS), 3
An Empirical Evaluation of the Placebo
Run-in, 41
RANDOMIZED CONTROLLED TRIALS
The Clinical-Economic Trial: Promise,
POSTERIOR DISTRIBUTION
Problems, and Challenges, 377
Prime Time for Bayes, 313
Observational versus Randomized Medical
Device Testing Before and After
POWER
Approval — The Atherectomy-
Design and Analysis of Multiarm Clinical versus-Angioplasty Controversy,
Trials with Survival Endpoints, 119
143
PREOPERATIVE RISK ASSESSMENT
RECRUITMENT
Requirements for Controlled Clinical Trials
Response Rates to Six Recruitment Mailing
of Preoperative Cardiovascular
Formats and Two Messages about a
Risk Reduction, 89
Nutrition Program for Women
50-79 Years Old, 422
PREOPERATIVE CARDIAC TESTING
Requirements for Controlled Clinical Trials
RECURRENT DEPRESSION
of Preoperative Cardiovascular
Cost Utility Analysis of Maintenance
Risk Reduction, 89
Treatment for Recurrent
Depression, 17
PREVENTION TRIALS
Response Rates to Six Recruitment Mailing
REGISTER OF TRIALS
Formats and Two Messages about a
UKCCCR Register of U.K. Cancer Trials,
Nutrition Program for Women
50-79 Years old, 422 172
REPEATED MEASURES EXPERIMENTS
PRIOR DISTRIBUTION
Sample Size Calculations for Repeated
Prime Time for Bayes, 313
Measures Experiments (letter), 449
PROSTATE CANCER
Design of the Prostate Cancer Prevention RESPONSE RATES
Trial (TCPT), 150 Response Rates to Six Recruitment Mailing
Formats and Two Messages about a
PROTOCOL Nutrition Program for Women
50-79 Years Old, 422
Dose-Ranging Trials: Guidelines for Data
Collection and Standardization
Descriptions, 319 RISK DIFFERENCE ESTIMATORS
A Further Look at the
PULMONARY FUNCTION TESTS Cochran-Mantel-Haenszel Risk
Response to S.J. Day Letter (letter), 447 Difference (letter), 359
Subject Index for Volume 16
RUN-IN THERAPEUTIC TRIALS
An Empirical Evaluation of the Placebo On the Role, Design, and Analysis of
Run-in, 41 Disease Prevention Trials, 249
SAMPLE SIZE TIME-DEPENDENT RATES
Comment in the Substitution of z for t and Sample Size Calculation for Complex
on Hotelling’s T? for Repeated Clinical Trials with Survival
Measures (letter), 451 Endpoints, 295
Design and Analysis of Multiarm Clinical
Trials with Survival Endpoints, 119 TRIAL REGISTRY
Sample Size Calculations for Repeated UKCCCR Register of U.K. Cancer Trials,
Measures Experiments (letter), 449 172
SCALES
TYPE I ERROR
Assessing the Quality of Randomized
Design and Analysis of Multiarm Clinical
Controlled Trials: An Annotated
Trials with Survival Endpoints, 119
Bibliography of Scales and
Checklists, 62
UNCONDITIONAL POWER
Sample Size Calculation for Complex
SICKLE CELL ANEMIA
Clinical Trials with Survival
Design of the Multicenter Study of
Endpoints, 295
Hydroxyurea in Sickle Cell Anemia,
432
UTILITY FUNCTION
Prime Time for Bayes, 313
SICKLE CELL CRISES PREVENTION
Design of the Multicenter Study of
VALID ANALYSIS
Hydroxyurea in Sickle Cell Anemia,
Comments on NIH Clinical Trials Valid
432
Analysis Requirements, 304
SOCIETY FOR CLINICAL TRIALS
WOMEN
Sixteenth Annual Meeting, 3S
Commentary Regarding “Inclusion of
Women and Minorities in Clinical
STANDARDS
Trials and the NIH Revitalization Act
Dose-Ranging Trials: Guidelines for Data
of 199— 3Th e Perspective of NIH
Collection and Standardized
Clinical Trialists,” 307
Descriptions, 319
Comments on NIH Clinical Trials Valid
Analysis Requirements, 304
STRATIFICATION
Discussion of “Inclusion of Women and
A Simple Measure in Defining Optimal
Strata in Clinical Trials, 164 Minorities in Clinical Trials and the
NIH Revitalization Act of 1993 — The
STUDY ARCHIVING Perspective of NIH Clinical
Interim Reports, Participant Closeout, and Trialists,” 301
Study Archives, 137S Inclusion of Women and Minorities in
Clinical Trials, 290
SUBJECTIVITY Inclusion of Women and Minorities in
Prime Time for Bayes, 313 Clinical Trials and the NIH
Revitalization Act of 1993—The
SURVIVAL ANALYSIS WITH Perspective of NIH Clinical
COVARIATES Trialists, 277
David Byar’s Approach to the Analysis of Response to Discussants’ Letters, 310
Survival Data with Covariates, 259 Response to “Inclusion of Women and
Minorities in Clinical Trials and the
SURVIVAL ENDPOINTS NIH Revitalization Act of 1993 — The
Design and Analysis of Multiarm Clinical Perspective of NIH Clinical
Trials with Survival Endpoints, 119 Trialists,” 286, 289, 293, 296, 299